NewAmsterdam Pharma Company N.V. (NAMS) is in Healthcare, Biotechnology, based in Netherlands, listed on NasdaqGM. Market cap 2.54B USD. 52-week range 20.91 to 42.20 USD. Data as of 2026-10-09.
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's ...